Skip to main content

Ingenuity and Wyeth Expand Software Licensing Deal

NEW YORK, Feb. 3 (GenomeWeb News) - Wyeth Pharmaceuticals and Ingenuity Systems have expanded a license agreement between the companies pertaining to Ingenuity's Pathways Analysis software, the companies said today.


Wyeth's researchers "downstream in the pharmaceutical value chain" would gain access to the software, Ingenuity CEO Jake Leschly said in the statement.


Financial terms of the expanded agreement were not disclosed.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.